Featured Researcher: Roland Chen – Bristol Myers Squibb

Roland Chen, MD

Roland Chen, MD

Senior Vice President and Head, Cardiovascular and Neuroscience Development, Global Drug Development

Central New Jersey


Roland Chen serves as the head of Cardiovascular Development within Bristol Myers Squibb’s Global Drug Development organization. In this role, Roland and his team oversee late-stage development of potential medicines for patients with cardiovascular conditions, applying the strong foundation of research and insights generated through years of cardiovascular (CV) experience within the company. Through the study of these late-stage assets, Roland and his team hope to develop new medicines with the potential to address the unmet needs of patients affected by thrombotic complications, cardiomyopathy and heart failure, among other conditions.


“Cardiovascular disease remains the leading cause of death in the United States and worldwide,” he said. “We hope to find treatment options that address the underlying mechanisms that lead to cardiovascular conditions, and ultimately identify approaches and medicines that will provide substantial benefit for patients in need.” 


Roland has been a part of Bristol Myers Squibb’s talented team of researchers for over two decades, starting immediately after his post-doctoral fellowship in medical informatics at Yale. Roland first joined Bristol Myers Squibb in the Health Outcomes Research group. He has spent most of his time at the company within global clinical development and also has worked within the global patient safety organization. 


Roland graduated from Princeton University with a bachelor’s degree in chemical engineering and went on to earn his master’s degree in electrical engineering from Stanford University, before earning his MD from the University of Pennsylvania. He completed his residency in internal medicine at the Beth Israel Hospital in Boston.

Interests and Expertise

For Roland, his long-standing commitment to develop potential medicines for patients in need stems from the opportunity to work alongside talented colleagues, whose passion and commitment to science are continuing to drive novel research and development advancements.  


“What initially drew me to Bristol Myers Squibb were the inspired and talented researchers with whom I would have a chance to work,” he said. “I'm hoping that the work my colleagues and I do will enable us to develop treatments that fundamentally make a positive impact on the lives of patients with cardiovascular diseases.” 


When Roland isn’t focused on the next wave of potential treatment options for patients, he enjoys spending time with his family, and can often be found partaking in sports such as running and cycling.